Healthcare

Amicus Therapeutics – Focusing on Rare and Orphan Illness

Amicus Therapeutics is a biopharmaceutical company that is based in Cranbury in New Jersey. It’s an American public company which was founded in 2002, and it became public in 2007 under NASDAQ trading symbol. Before their IPO, Amicus Therapeutics was funded by several venture capital firms such as Canaan Partners, New Enterprise Associates and Radius Ventures.   Amicus Therapeutics focuses mainly on rare and orphan illness. They specialize mainly in disorders largely known as lysosomal storage disorders. The development of the company’s product is largely dependent on the CHART. In 2014, Amicus Therapeutics gained the recognition of being having with no doubt the largest small molecule pharmacological chaperones portfolio within the pharmaceutical industry.   By Feb. 2014, Amicus Therapeutics had no retailed products. It most marketed product was migalastat whose trade name is Galafold (AliveNewspaper). Migalastat is a pharmacological chaperone that is used in the treatment of Fabry disease. The main…